Vosoritide
Vosoritide
Vosoritide (pronounced vo-so-ri-tide) is a synthetic peptide analogue of C-type natriuretic peptide (CNP) that is used in the treatment of achondroplasia, a genetic disorder that is the most common cause of dwarfism.
Etymology
The name "Vosoritide" is derived from the words "Vaso", referring to its vasodilatory effects, and "ritide", a common suffix used in peptide drugs.
Usage
Vosoritide is used to treat children with achondroplasia whose bones have not yet finished growing. It works by stimulating bone growth, thereby increasing height in children with this condition. The drug is administered by subcutaneous injection once daily.
Mechanism of Action
Vosoritide mimics the effects of CNP, a molecule that is naturally produced in the body and plays a key role in bone growth. By binding to the natriuretic peptide receptor B (NPR-B) in growth plate chondrocytes, vosoritide increases intracellular cyclic guanosine monophosphate (cGMP), which in turn stimulates bone growth.
Side Effects
Common side effects of vosoritide include injection site reactions, hypotension, and headache. Less common side effects may include vomiting, cough, and fever.
Related Terms
- Achondroplasia
- C-type Natriuretic Peptide (CNP)
- Natriuretic Peptide Receptor B (NPR-B)
- cyclic Guanosine Monophosphate (cGMP)
External links
- Medical encyclopedia article on Vosoritide
- Wikipedia's article - Vosoritide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski